Nobel Prize in Physiology or Medicine 2025

The Nobel Prize 2025: Resetting the Immune System’s Moral Compass

On October 6, 2025, Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi were jointly awarded the Nobel Prize in Physiology or Medicine for their groundbreaking research on regulatory T cells (Tregs) and peripheral immune tolerance. Their work redefined how immunologists understand the body’s defense system and its decision-making processes — specifically, how it prevents rogue immune cells from attacking healthy tissues even as it combats external pathogens. The implications range far beyond the laboratory, touching the core of how we fight autoimmune diseases, cancer, and chronic inflammation.

What the Treg Discovery Means for Medicine

The laureates’ discovery of regulatory T cells has been directly linked to the development of therapies tackling autoimmune disorders like rheumatoid arthritis, lupus, and multiple sclerosis. By 2024, global pharmaceutical investment in immunoregulatory therapies reportedly exceeded $14 billion, with companies such as Genentech and Novartis at the forefront. Their innovations, based on Treg pathways, are now in advanced clinical trials for diseases as complex as Type-1 diabetes.

The Karolinska Institute's selection highlighted another critical finding from the research: regulatory T cells often accumulate around tumors, offering cancerous growths a shield from cytotoxic attack. This paradox — where the immune system inadvertently aids malignant cells — paved the way for immunotherapy trials targeting Treg suppression, a method now used alongside checkpoint inhibitors in treating advanced life-threatening cancers like melanoma and lung cancer.

India, which lacks sufficient access to immunotherapy, acknowledges the potential of such breakthroughs. The Department of Biotechnology allocated ₹4,500 crores to cancer and autoimmune disease research under its National Biopharma Mission for the current decade. However, the gap between such basic research and affordable, locally produced therapeutics remains significant, as evidenced by India’s heavy reliance on international patents.

A Sharp Divide: Progress Versus Risks

Supporters argue the laureates’ findings bring clarity to immune regulation at the most fundamental level. Regulatory T cells are crucial for preventing autoimmune conditions that result when the immune system indiscriminately attacks healthy cells. Without them, diseases like Hashimoto’s thyroiditis and Crohn’s disease would be far more rampant. The discovery also launched the clinical domain of peripheral tolerance, which offers the hope of more targeted transplantation medicine by reducing rejection risks, especially in liver and kidney transplants.

Yet the revelations are not without their own dilemmas. According to critics like Dr. Jonas Fins from the European Institute for Immunology, research on suppressing Tregs in cancer therapy might inadvertently trigger autoimmune disorders. There is no robust mechanism yet to balance the suppression of Tregs around malignant cells while retaining their efficacy elsewhere in the body. Excessive manipulation of peripheral immune tolerance, especially through widespread drug trials, might unleash new classes of diseases born out of unintended immunological imbalance.

India must tread carefully here. The country’s clinical trial ecosystem is under scrutiny for ethical lapses, as highlighted in recent Parliamentary debates. Regulatory oversight remains thin, with no clear policy under the Drugs and Cosmetics Act addressing immune-modulation therapeutics specifically. The absence of rigorous data collection (e.g., through a national immunological registry) makes it hard to predict the downstream consequences of such interventions.

What Japan Has Already Done

Japan offers a compelling comparison. Immunologist Shimon Sakaguchi, one of the laureates, spearheaded much of this research at Kyoto University. Japan swiftly translated his findings into clinical trials backed by state-funded initiatives under its Immunomics Research Program, launched in 2010 with a ₹2,000 crore allocation. By 2022, Japan had developed an FDA-approved Treg-based treatment for severe rheumatoid arthritis, and its bioscience patents rose by 25% over a decade due to these early investments.

India’s approach can learn from Japan’s emphasis on public research funding combined with private-sector collaboration. While the National Biopharma Mission has opened doors, it lacks specific provisions mandating patent utilization within Indian firms, perpetuating dependency on foreign drug corporations. Japan’s model of state-coordinated patent implementation is worth replicating to prevent scientific discoveries here from becoming commercially unreachable.

Where We Stand

The Nobel Prize is as much an acknowledgment of scientific achievement as it is an invitation to future challenges. Immunology’s current frontier — targeted immune tolerance — holds enormous promise for mitigating chronic diseases, but equally ominous risks. India’s policy framework is not yet robust enough to capitalize on this knowledge responsibly. The Ministry of Health and Family Welfare must restructure its immunological research mandate, incorporating safeguards against misuse while scaling indigenous infrastructure for translational medicine.

Ultimately, the nobility of discovery rests on equitable access. If Treg-based therapies remain restricted to affluent economies with advanced biotech industries, their revolutionary potential will be undermined. This is the moral crossroads at which India — and the world — currently stands.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions